Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 25, 2020
Emer Cooke Receives Nomination for Position of EMA Executive Director
Author(s)Pharmaceutical Technology Editors
Emer Cooke, currently the director of the Regulation and Prequalification Department at the World Health Organization (WHO) in Geneva, has been nominated by EMA’s management board to be the new executive director of EMA.
Advertisement
Emer Cooke, currently the director of the Regulation and Prequalification Department at the World Health Organization (WHO) in Geneva, has been nominated by the European Medicines Agency’s (EMA’s) management board to be the new executive director of EMA.
Selected from a shortlist of candidates that had been created by the European Commission (EC), Cooke has been invited to present a statement to the European Parliament’s Committee on Environment, Public Health, and Food Safety (ENVI) on July 13, 2020. The appointment of the position of EMA executive director will only be made after the ENVI meeting.
Cooke has more than 30 years’ experience within international regulatory affairs, it was revealed in a June 25, 2020 press release discussing her nomination. Cooke has worked for the pharmaceutical unit of the EC from 1998 until 2002 and then at EMA between 2002 and 2016, where she was positioned as the head of inspections and head of international affairs, among other roles.
Source:
Advertisement
Related to this article
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Advertisement
Advertisement